Elkhart Plastics, A Myers Industries Company, Introduces Vertical Water Tanks to Help Protect People, Property, and Resources
AKRON, Ohio, May 06, 2025--(BUSINESS WIRE)--Elkhart Plastics, a Myers Industries Company and recognized leader in rotational molding, introduced its new Vertical Water Storage Tanks—broadening its product portfolio and marking its entry into a new market.
Designed to protect people, livestock, crops, and property, these vertical storage tanks support a wide range of commercial and residential water needs. From crop irrigation and livestock care to manufacturing processes and fire suppression, they provide reliable access to water—critical in regions facing water scarcity. The tanks also protect resources by enabling bulk water storage, well water collection, and rainwater harvesting.
Elkhart's Vertical Water Storage Tanks have been engineered for durability and cost-efficiency, making them the ideal choice in many operations. Constructed from UV-resistant, FDA-approved high-density polyethylene, the tanks come with a 10-year limited warranty and currently are available in four sizes—1,000-, 1,500-, 2,500-, and 3,000-gallon capacities—with more sizes planned.
The tanks also feature key design elements that enhance performance:
Multiple connection points —risers and tie-downs with flat surfaces offer greater flexibility for additional fittings
Dual manway lids —provide more flexibility for secure top-down access
Integrated air bleeds —help maximize fill efficiency and minimize fill time
Tough tank top—large radii and increased wall thickness safeguard against sun exposure
"The launch of our Vertical Water Storage Tank underscores our commitment to innovation, quality, and sustainability," said Cullen Jones, V.P. of Sales for Rotational Molding at Myers Industries. "As water becomes an increasingly precious resource, effective storage and conservation are vital to maintaining ecosystems, supporting human populations, and ensuring a sustainable future. These tanks demonstrate our dedication to delivering economically viable and environmentally responsible solutions to customers."
The Vertical Water Storage Tanks are available for purchase directly from Elkhart or through the company's dealer network.
About Elkhart Plastics
Founded in 1988, Elkhart Plastics LLC is a recognized leader in rotational molding. The company engineers and manufactures a wide array of custom and proprietary products across its North American facilities, including the TUFF Series line of intermediate bulk containers and Connect-A-Dock, a versatile line of floating docks and marine accessories. In 2020, Elkhart became part of Myers Industries, joining a family of companies with expanded manufacturing capabilities and strengthening Elkhart's ability to offer customers greater value, resources, and expertise. Visit myersengineeredsolutions.com to learn more about Vertical Water Storage Tanks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. ('Replimune or the 'Company') (NASDAQ: REPL). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See On July 22, 2025, before the market opened, Replimune issued a press release entitled 'Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma.' The press release stated that Replimune had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.' The press release stated that the CRL 'indicates that the FDA is unable to approve the application in its present form. The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.' On this news, Replimune common stock plummeted over 73% during intraday trading on July 22, 2025. To learn more about the Replimune investigation, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Yahoo
2 hours ago
- Yahoo
The FDA Just Approved Juul's E-Cigarettes. Does That Make Altria Stock a Buy Here?
Following a prolonged and high-stakes legal battle, the U.S. Food and Drug Administration (FDA) granted Juul marketing approval for its e-cigarettes. For Altria (MO), a tobacco giant and an early investor in Juul, this is an interesting development. While this is a positive on the regulatory front for the wider e-cigarette industry in general and the company's own NJOY brand, it also raises competitive pressure for Altria in the vaping market as it no longer holds a position in Juul. Investors should note that at the end of March, Altria also announced that it would halt sales of its NJOY e-cigarettes in the U.S. due to a patent infringement ruling in favor of Juul. More News from Barchart Opendoor Stock Is Surging Higher in a Frenzied Retail Rally. How Should You Play OPEN Shares Here? This Penny Stock Wants to Become the MicroStrategy of Dogecoin Robinhood Stock Stumbles as S&P 500 Inclusion Is Once Again Off the Table for HOOD Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! About Altria Altria is one of the most popular tobacco companies in the world with iconic brand such as Marlboro, Copenhagen, Skoal, and Black & Mild in its portfolio. Its diversified presence also includes smokeless products, cigars, and nicotine alternatives such as the aforementioned NJOY. MO stock is up 13.4% on a YTD basis, with the company boasting a market cap of $99 billion. Tobacco stocks are known for having high dividend yields, but Altria's is especially high at 6.9%. Moreover, the company is a 'Dividend King,' having increased dividends consecutively over the past 54 years. So, how should one play MO stock now? Let's have a closer look. Boring But Steady Financials When it comes to Altria's numbers, they are nothing extraordinary. In fact, they are quite boring, marked by not much growth. Over the past 10 years, the company's revenue and earnings have reported CAGRs of just -0.4% and 8%, respectively. Following this trend, the first quarter was a mixed bag for the company. While net revenues of $5.5 billion denoted a yearly decline of 5.7%, adjusted earnings went up by 6% in the same period to $1.23. A decline of 13.3% seen in shipments of its flagship Marlboro cigarettes was a primary reason for the overall decline in sales. Meanwhile, while volumes for NJOY consumables increased by 23.9% from the previous year to 13.5 million units, NJOY devices witnessed a significant 70% decline in reported shipments. Overall, its retail share of consumables increased to 6.6%. Altria closed the quarter with a cash balance of $4.73 billion. This was above its short-term debt levels of $2.6 billion. For 2025, the company expects its earnings to be in the range of $5.30 to $5.45 per share, the midpoint of which would represent growth of 5% from 2024. Altria's Tailwinds and Headwinds One growth product for Altria is its On! nicotine pouch brand, which has been gaining ground, and could take the lead in place of NJOY in its alternative portfolio. The company grew the market share of its On! pouches to 8.8%, up from 7% in the year-ago period. Sales volumes also grew to 39.3 million cans, a jump of 18% from a year ago. Notably, the company sees potential for further expansion, especially with new flavors planned and the possibility of launching On! PLUS in the U.S., a variant currently sold in select European markets. Further, despite shifting industry trends, Altria's cigarette business remains strong. Marlboro still holds nearly 46% of the U.S. cigarette market, maintaining its dominance. Additionally, the Black & Mild brand also continues to perform well in the machine-made cigar category. Meanwhile, on the heated tobacco front, often referred to as HTC, Altria is exploring two new products: Ploom and SWIC. Both are marketed as reduced-risk alternatives. Ploom, a product developed with Japan Tobacco, is awaiting FDA authorization before a potential U.S. debut. While timelines aren't certain, Altria seems optimistic. The other option, SWIC, features a capsule-style heated tobacco system and might appeal to smokers who haven't transitioned to vape products but are still looking for non-combustible alternatives. That said, not all bets have worked out. The $12.8 billion investment in Juul Labs failed to pan out, and Altria eventually abandoned that stake. Perhaps even more problematic was losing the right to sell IQOS in the U.S., a product many had viewed as a cornerstone of its reduced-risk portfolio. Though On! is gaining, the broader picture in oral tobacco tells a different story. Altria's overall share in the segment slipped from 37.8% to 34.7% year-over-year. Meanwhile, the NJOY ACE platform is in limbo. The U.S. International Trade Commission issued cease-and-desist and exclusion orders, preventing Altria from importing or selling it domestically for now. This followed a ruling that NJOY ACE had infringed on four Juul Labs patents. Altria could try modifying the device to bypass those patents, but that approach may be risky. Any major redesign would likely trigger a fresh FDA application, and the approval process is neither quick nor guaranteed. Analyst Opinions on MO Stock Thus, analysts have deemed MO stock to be a 'Hold' with a mean target price of $57.73, which has already been surpassed. However, the high target price of $65 denotes an upside potential of about 8% from current levels. Out of 14 analysts covering the stock, four have a 'Strong Buy' rating, eight have a 'Hold' rating, one has a 'Moderate Sell' rating, and one has a 'Strong Sell' rating. On the date of publication, Pathikrit Bose did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
REPL BREAKING NEWS: Replimune Group, Inc. Stock Plummets 75% after FDA Response Letter – BFA Law Announces Securities Fraud Investigation and Urges Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)--Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal securities laws. Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Replimune Group, Inc. (NASDAQ: REPL) for potential violations of the federal securities laws. Share If you invested in Replimune, you are encouraged to obtain additional information by visiting: Why is Replimune being Investigated? Replimune is a clinical-stage biotechnology company focused on developing and commercializing oncolytic immunotherapies for the treatment of cancer. Replimune's lead product candidate is RP1, a treatment for melanoma. On June 6, 2024, the Company announced positive top line results from its IGNYTE Phase 1/2 clinical trial for RP1 in combination with the immunotherapy drug nivolumab. On November 21, 2024, Replimune announced that it had submitted a biologics license application ('BLA') to the FDA for RP1 on the strength of the results of the IGNYTE Phase 1/2 trial. During the relevant period, the Company repeatedly touted the results of the IGNYTE Phase 1/2 trial. In truth, the IGNYTE Phase 1/2 trial design was not adequate to produce reliable results. The Stock Declines as the Truth is Revealed On July 22, 2025, Replimune announced that it received a Complete Response Letter from the FDA regarding the BLA for RP1. According to the Company, '[t]he FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.' More specifically, 'the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.' On this news, the price of Replimune stock fell more than 75% on July 22, 2025. Click here for more information: What Can You Do? If you invested in Replimune you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
